WD-40 Company has outlined its financial roadmap for fiscal year 2027, projecting robust growth in net sales and earnings per share, underpinned by an anticipated recovery in its gross margin. These forward-looking statements provide a clear indication of the company’s strategic objectives and operational confidence for the coming years.
FY 2027 Sales and EPS Outlook
For fiscal year 2027, WD-40 is targeting net sales growth in the range of 4% to 7%. This projection signals the company’s confidence in expanding its top-line performance, reflecting potential market share gains or increased product demand across its portfolio. This growth rate suggests a steady, deliberate expansion strategy. Concurrently, the company anticipates its earnings per share (EPS) to reach between $6.40 and $6.70 for the same period. This specific profitability benchmark offers investors a detailed outlook on the expected return on their investment, indicating management’s focus on bottom-line performance alongside revenue expansion.
Gross Margin Rebound Expected
A crucial element supporting these ambitious financial targets is the expected rebound in gross margin. The company noted that its gross margin had experienced a low point in the fourth quarter, suggesting that the FY 2027 projections factor in a significant improvement from this recent performance. This anticipated recovery could stem from various operational efficiencies, such as optimized supply chain management, favorable input cost trends, or strategic pricing adjustments that enhance profitability. The focus on gross margin recovery is pivotal, as it directly impacts the company’s ability to convert revenue into profit and fund future growth initiatives.
These detailed financial targets from WD-40 offer a transparent view into its future performance expectations, highlighting both growth ambitions and a focus on margin improvement as key drivers for shareholder value in fiscal year 2027. Investors will likely scrutinize these projections for signs of sustainable operational health and strategic execution.
